Introduction
============

Pulmonary rehabilitation (PR) is a well-recognized intervention in the management of individuals with COPD that is designed to improve patients' physical and psychosocial conditions by providing tailored interventions including exercise training, education, and behavioral changes given by an interdisciplinary team of healthcare professionals.[@b1-copd-13-3131]

There is strong evidence that exercise training lessens ventilatory requirement and reduces the degree of dynamic lung hyperinflation leading to improved arterial oxygen content and central hemodynamic responses, thus increasing systemic muscle oxygen availability.[@b2-copd-13-3131] In previous studies, it has been shown that the combination of improved mechanical efficiency and improved respiratory and skeletal muscle strength[@b3-copd-13-3131] may determine desensitization to dyspnea[@b4-copd-13-3131] and consequently reduce dynamic hyperinflation.[@b2-copd-13-3131]

These physiological benefits apply to all COPD patients, irrespective of the degree of disease severity,[@b5-copd-13-3131] and are associated with improved exercise tolerance, functional capacity, and quality of life,[@b6-copd-13-3131] thereby reducing breathlessness and hospital admissions and improving recovery after exacerbation.[@b1-copd-13-3131] However, the responses to PR may vary significantly among individuals. Many studies were not able to detect significant changes in forced expiratory volume in the first second (FEV~1~), forced vital capacity (FVC), and FEV~1~/FVC values after PR.[@b7-copd-13-3131]--[@b9-copd-13-3131] Thus, a wide range of outcome measures has been described to assess clinically relevant outcomes after PR. The decision to incorporate more sophisticated tests mainly depends on the available resources and the philosophy of each PR center.[@b10-copd-13-3131] Recently, Smargiassi et al have demonstrated the possible role of ultrasound (US) measurement of diaphragm thickness and thickening at the zone of apposition (zapp) at the end of a maximal inspiration might be a useful tool to estimate lung hyperinflation.[@b11-copd-13-3131] Moreover, US analysis of the diaphragmatic excursion has been correlated with bronchial obstruction.[@b12-copd-13-3131] Thus, we hypothesized that US variation of diaphragm mobility and thickness before and after a PR program may represent good markers of the effects of a successful PR program in COPD patients and that these changes may correlate with positive outcome measures postrehabilitation.

Therefore, we aimed to estimate the role of US assessment of diaphragm function in COPD patients undergoing a PR program and in the detection of postrehabilitation outcomes.

Materials and methods
=====================

Study design and participants
-----------------------------

This prospective observational study was conducted in the Pulmonary Rehabilitation Unit at Policlinico University Hospital, Catania, Italy, between November 2017 and March 2018. Inclusion criteria were as follows: a confirmed diagnosis of COPD according to GOLD criteria,[@b13-copd-13-3131] current or former smoke history of at least 10 pack/years with clinical indication for PR according to British Thoracic Society guidelines[@b14-copd-13-3131] and no exacerbation in the past 12 weeks; patients with pacemaker, unstable angina, recent myocardial infarction, lung cancer, neurological diseases, pleural effusion, interstitial lung diseases, and recent major surgery were excluded.

Forty-seven out of fifty-five consecutive COPD patients (41 males, 87.3%) were referred for PR during the study period; thirty-seven of those patients met the inclusion criteria and were enrolled in the present study. Twenty-five patients fully completed the 12-week PR program and were considered for data analysis.

Methods
-------

Eligible patients were assessed for pulmonary function, 6-minute walking test (6MWT), and US assessment of diaphragmatic function and of *quadriceps femoris* transverse section; all the measurements were done before and after PR. Dyspnea and health status were graded using the modified Medical Research Council (mMRC) dyspnea scale[@b15-copd-13-3131] and COPD Assessment Test (CAT) scale,[@b16-copd-13-3131] respectively; BODE index[@b17-copd-13-3131] and Charlson index[@b18-copd-13-3131] were also used for calculation. Written informed consent was obtained from all participants; Institutional Review Board of Policlinico Hospital, Catania, approved the study (IRB \# 0017237).

Pulmonary function tests
------------------------

Pulmonary function tests, spirometry and plethysmography (Medical Graphics, St Paul, MN, USA), were performed following standard protocols,[@b19-copd-13-3131],[@b20-copd-13-3131] based on reference equations.[@b21-copd-13-3131] Arterial blood gas (ABG) analysis was performed in all patients.

Ultrasonographic measurements
-----------------------------

US measurements were performed using an US machine with probes of 2--6 and 6--15 MHz (Sonoscape A6 e Logic Book GE). Diaphragm US recordings were performed as previously described[@b11-copd-13-3131] by the same investigator (Dr Teresa Augelletti), a physician trained in internal and thoracic echography, who was blinded to patients' PR outcomes. The excursion of right hemi-diaphragm during quiet breathing, at tidal volume (CV), and during deep breathing, at total lung capacity (TLC), starting from normal end-expiratory volume (functional residual capacity, FRC) was measured using a convex probe of 3.5 MHz with M-mode technique, and measurements were obtained at CV and at TLC. We considered normal values as previously defined.[@b22-copd-13-3131],[@b23-copd-13-3131] Measurements of diaphragm kinetics at the zapp were performed as previously described,[@b24-copd-13-3131] with a probe of 6--15 MHz. Diaphragm thickness was measured at zapp using B-mode US imaging. The zapp was measured at the closest point to the "curtain sign" in which the two hyperecogenic parallel layers of diaphragm were clearly identified in the right intercostal position. We measured the distance of zapp from the skin, its thickness (Szapp), and its length (Lzapp) at different lung volumes: FRC and TLC. It was not possible to evaluate Lzapp at the end of maximal expiration (residual volume, RV) for which a longer linear probe is required. We considered only US measurements obtained at patients' right side for statistical analysis, as left side offers a poor acoustic window in the majority of patients, as in previous studies.[@b25-copd-13-3131] Measurements of quadriceps femoris transverse section were performed as previously described,[@b26-copd-13-3131] taking into account the average of three subsequent measurements. The percentages of change (Δ%) of US measurements before and after PR for diaphragm zapp were defined as ΔLzapp TLC%, ΔLzapp FRC%, ΔSzapp TLC%, ΔSzapp FRC%; the Δ% for diaphragmatic excursion was defined as ΔQuiet Breathing% and ΔDeep Breathing%. The percentage of change of rectus femoris area was outlined as ΔRectus Femoris Area%.

Pulmonary rehabilitation
------------------------

All subjects participated in a 12-week, 3 sessions per week, out-patient-based PR program. The PR training included upper and lower extremity endurance and strength training.[@b1-copd-13-3131] Exercise sessions were conducted for 60 minutes: 10-minute warm-up period, 40-minute aerobic activity, and 10-minute cool-down period. The aerobic activity was composed of the following: 20 minutes of lower limb endurance training by walking on a treadmill or cycling with an exercise intensity target set at a speed of 60% of the speed of their 6MWT, upper extremity endurance training (arm exercise lifting or stretching elastic bands), and strength training (weight lifting, diagonal arm raises, arm abduction into elevation and reverse, forward flexion, and reverse and straight leg rises). Work rate, SpO~2~, heart rate, dyspnea scores, and leg fatigue were monitored during the sessions.

Outcome measurements
--------------------

We wanted to explore patients' interindividual changes of clinical and US parameters after PR. Moreover, to determine the clinically meaningful responsiveness and effectiveness of PR, we evaluated whether patients achieved the accepted minimal clinically important difference (MCID) for the 6MWT and for the CAT score, after the 12-week PR programs. The MCID considered for 6MWT was 54 m as previously described.[@b27-copd-13-3131] The MCID for the CAT has not been formally established but, based on its relationship with Saint George Respiratory Questionnaire (SGRQ), where a change of 4 points in the total score has been shown to represent the minimal clinically significant change and that this was equivalent to a decrease of 1.6 points in CAT score, we considered a reduction of at least 2 points in CAT score after PR as the MCID for CAT.[@b28-copd-13-3131] Furthermore, we wanted to explore if the interindividual percentage of change in Lzapp measured by US was able to discriminate between patients who "markedly improved" after PR reaching the MCID at 6MWT and CAT.

Statistical analysis
--------------------

Baseline measurements and results were expressed as mean ± SD or medians and interquartile ranges for continuous variables and percentage for categorical variables. Intraindividual changes in pulmonary function, dyspnea scores, US measurements, and 6MWD post-PR were assessed by Wilcoxon-signed rank test. We used the nonparametric analysis because the assumption of normality, assessed with Shapiro-Wilk test, was not fulfilled or the presence of outliers was detected for all the variables.

Spearman rank order correlation (rho) was used to estimate the strength of relationships between the intraindividual change of Lzapp at FRC (ΔLzapp%) and PR outcome expressed as intra-individual change of 6MWD.

Based on the MCID target, at a second stage, we split our patients into two groups: Markedly improved: those who improved after PR and reached the minimally clinically important difference of \>54 m at 6MWD and a reduction of at least 2 points in CAT score;Slightly improved: those who improved after PR but were not able to reach the meaningful cutoff at 6MWD and CAT.

Mann--Whitney *U*-test was employed for comparisons between the groups of "markedly improved" patients (who reached the MCID for 6MWT and CAT) and "slightly improved" patients (who did not achieve the MCID for 6MWT and CAT).

In addition, the receiver operating characteristic (ROC) curves were constructed to assess the ability of ΔLzapp% to discriminate among "markedly improved" and "slightly improved" patients after PR. Youden index, a function of sensitivity and specificity, was calculated to find its maximal value for the determination of an optimal cutoff point of ΔLzapp% after PR in our population. A *P*-value \<0.05 was considered statistically significant. Statistical analyses were performed using SPSS 15.0.

Results
=======

The general and baseline characteristics of the study population are shown in [Table 1](#t1-copd-13-3131){ref-type="table"}.

All patients were clinically stable and in regular treatment with long-acting beta-2 agonist; 96% took a long-acting anticholinergic and 52% (n=13) were treated with inhaled corticosteroids. Patients continued their inhaled drug therapy throughout the study period. All patients attended the entire PR program and completed the 36 sessions (1 hour/session) planned.

All the patients significantly improved after PR in terms of pulmonary function, ABG, 6MWD, mMRC, and CAT score as shown in [Table 2](#t2-copd-13-3131){ref-type="table"}; statistically significant improvements after PR were observed also in US parameters of both diaphragm and quadriceps muscle measures as outlined in [Table 3](#t3-copd-13-3131){ref-type="table"}.

We found a moderate positive correlation between the intraindividual percentage of ΔLzapp% and the change in 6MWD before and after PR (rho=0.49, *P*=0.02, [Figure 1](#f1-copd-13-3131){ref-type="fig"}). When grouping our patients in markedly improved (those who improved after PR and reached the MCID of \>54 m at 6MWD and a reduction of 2 points of CAT) and slightly improved (those who improved after PR but were not able to reach the meaningful cutoff at 6MWD and CAT, respectively), we found that the intra-individual ΔLzapp% was significantly higher in the group of "markedly improved" compared to the group of "slightly improved" patients (mean rank=12.03±2.57 vs 6.88±4.37, respectively) (*P*=0.02) as shown in [Figure 2](#f2-copd-13-3131){ref-type="fig"}. The percentages of changes of US measurements between the group of "markedly improved" and "slightly improved" patients at 6MWT are shown in [Table 4](#t4-copd-13-3131){ref-type="table"}.

Similarly, we found a statistically significant increase in ΔLzapp% post-PR in the "markedly improved" patients (who reached the MCID for the CAT score) compared to "slightly improved" patients (who did not achieve the MCID goal) (10.70±3.20 vs 6.21±4.65, *P*=0.04), as shown in [Figure 3](#f3-copd-13-3131){ref-type="fig"}. All the percentages of changes of US measurements between the group of "markedly improved" and "slightly improved" patients at CAT score are shown in [Table 5](#t5-copd-13-3131){ref-type="table"}.

In addition, we plotted ROC curves to determine ΔLzapp% with the best sensitivity and specificity to discriminate between patients that "markedly improved" after PR (who reached the threshold of MCID for 6MWT and CAT) and "slightly improved" (who did not achieve the MCID goals). Based on the maximal Youden indexes, the cutoff value able to differentiate between "markedly improved" and "slightly improved" patients at the 6MWT after PR was a ΔLzapp% of ≥10% with a sensitivity and a specificity of 83% and 74%, respectively (CI 95% 0.64--1, *P*=0.02). The area under the ROC curve for ΔLzapp% was 0.83 ([Figure 4](#f4-copd-13-3131){ref-type="fig"}). A cutoff value of \>9% of ΔLzapp% had a positive predictive value in discriminating MCID for the CAT after PR. Considering this cutoff, the sensitivity and the specificity were 80% and 62%, respectively (CI 95% 0.55--0.97, *P*=0.04), and the area under the ROC curve for ΔLzapp% was 0.76 ([Figure 5](#f5-copd-13-3131){ref-type="fig"}).

Discussion
==========

The results of our study showed that the US assessment of diaphragmatic function was able to accurately identify COPD patients who meaningfully improved after PR.

To our knowledge, this is the first study investigating the role of diaphragm US as a possible outcome of PR in subjects with COPD.

Since the available nonimaging diagnostic tests to assess diaphragmatic function are complex and relatively invasive,[@b29-copd-13-3131] several functional imaging techniques have been used over time; the most simple method to perform and easy to interpret is the fluoroscopy,[@b30-copd-13-3131],[@b31-copd-13-3131] which can assess the dome excursion through the sniff test but it involves a significant exposure to ionizing radiation.

Alternatively, chest X-ray and computed tomography (CT) have been used but the possibility of having a dynamic imaging is limited; dynamic magnetic resonance imaging (MRI) has also been described, but it has the limitation of high costs.[@b32-copd-13-3131]

Moreover, drawbacks of all these techniques include limited availability and the need for patient transport. Recently, Chun et al[@b33-copd-13-3131] showed that fluoroscopy is an effective and cost-saving technique for evaluating pulmonary rehabilitation in a small cohort of COPD patients compared with CT or MRI, but Houston et al had already clearly stated that US has several advantages over fluoroscopy and it should be considered as the method of choice when studying diaphragm function.[@b34-copd-13-3131]

The US assessment of diaphragmatic function has been widely and successfully used to detect the presence of diaphragm dysfunction as a postsurgical complication,[@b35-copd-13-3131] to identify the occurrence of ventilator-induced diaphragm injury,[@b36-copd-13-3131],[@b37-copd-13-3131] to evaluate diaphragm dome motion[@b25-copd-13-3131] during spontaneous breathing weaning trials,[@b38-copd-13-3131] to quantify the work of breathing[@b39-copd-13-3131] and titrate ventilatory support,[@b39-copd-13-3131]--[@b41-copd-13-3131] and to predict extubation success.[@b42-copd-13-3131] This technique has been studied in COPD patients, showing a reduction in diaphragmatic excursion and thickening in the subset of patients with more pronounced air-trapping[@b11-copd-13-3131],[@b43-copd-13-3131],[@b44-copd-13-3131] and to establish diaphragmatic dysfunction,[@b45-copd-13-3131] but no studies have explored the use of this technique in the PR settings.

The first remarkable finding of this study is that the sonographic evaluation of the diaphragm is able to document a significant change of diaphragmatic excursion after PR in COPD patients. Our study also strengthened the results of previous studies[@b26-copd-13-3131],[@b46-copd-13-3131] about the utility of ultrasound measurements of the rectus femoris area as a noninvasive tool of measuring muscle mass change in patients who underwent PR.

The portability and wide availability of US make sonographic evaluation of both diaphragm and quadriceps femoris ideally suited for a routine incorporation into the PR assessment, to complement a more complete appraisal of COPD patients undergoing PR, to measure individual's progresses, to potentially tailor PR program for each patient, and to evaluate its outcomes. Indeed, the US technique does not require any special effort, coordination, or cooperation, and therefore can be easily used also in older and more severe patients. Moreover, we can speculate that US diaphragmatic assessment may help in identifying the subpopulation of COPD patients with diaphragm muscle dysfunction and consequent ventilatory mechanics alterations that may expose patients at a major risk of reexacerbation due to a low maximum diaphragm excursion;[@b47-copd-13-3131] therefore, this technique can be helpful in phenotyping subgroups of COPD patients, identifying those who are potentially more frail and probably at higher risk of exacerbations and it might be even used as a criterion for assigning a rehabilitation priority in the waiting list for the inhospital PR program. Furthermore, US is an accurate, reproducible, and relatively easy to learn technique that needs little learning curve; therefore, even physiotherapists could use this tool in their clinical decision-making processes before and after PR, as already reported in the literature.[@b48-copd-13-3131]

The second important finding of our study is that the US assessment of diaphragmatic function may accurately predict the response to PR. In fact, in our study the intraindividual ΔLzapp% was significantly higher in patients who markedly improved after PR in terms of reaching a meaningful target (MCID) at 6MWT and CAT score. Moreover, our study showed that a cut-off value of \>9% ΔLzapp% showed a positive predictive value in discriminating clinically meaningful improvement both in the 6MWD and CAT scores of COPD patients after PR. Therefore, these findings should remind clinicians about the importance of diaphragm evaluation using thoracic US in daily clinical practice and that the identification of this percentage of change after PR may contribute in phenotyping COPD patients with a fast and non-invasive technique.

Last but not least, a sonographic study can demonstrate to patients the improvement of the muscle function with a simple visual image; therefore, we can speculate that this might be used as a coping strategy for patients, feeling involved in the management of their disease, and hopefully improving adherence to PR program. There are several limitations to the present study that should be mentioned. First, the relatively small number of patients might have influenced the results; second, we did not measure diaphragmatic thickness during inspiration that has been used as an indirect measurement of muscle fiber contraction; even though several different US techniques have been described so far, at the moment, no standardized approaches are recommended for a comprehensive study of diaphragm function.[@b49-copd-13-3131] Third, health-related quality of life measurements such as SGRQ were not recorded for all patients and therefore not suitable for data analysis. Moreover, we did not measure the maximal static inspiratory pressure and maximal static expiratory pressure. Finally, we have to consider that US can be operator dependent; in the present study, US data recordings were reported only by one physician, qualified in using ultrasonography in daily practice; therefore, the interobserver variability could not be evaluated. Nevertheless, we really believe that our results have important clinical implications that can still be generalized in the hospital-based settings.

In conclusion, our study supports the routine use of US diaphragmatic assessment before and after PR as an additional tool for the evaluation of clinical effects of PR in COPD patients. It provides a rapid, reliable, noninvasive and relatively easy-to-use approach that allows repeated measures and does not require patient's effort or coordination, and it should be used in combination with other exams to assess PR outcomes.
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![Correlation between Lzapp and 6MWT.\
**Note:** Spearman rank order correlation between the change (%) of Lzapp at FRC and the change (delta meters) in 6MWD before and after PR (rho=0.49, *P*=0.02).\
**Abbreviations:** Lzapp, diaphragm zone of apposition length; FRC, functional residual capacity; 6MWD, 6-minute walking distance; 6MWT, 6-minute walking test.](copd-13-3131Fig1){#f1-copd-13-3131}

![Difference in ΔLzapp% between patients with a minimal clinically significant difference for 6MWD after PR.\
**Notes:** Box plots illustrating the change (%) of Lzapp at FRC between patients who "slightly improved" (who performed a 6MWD of \<54 m) or "markedly improved" (who performed a 6MWD of \>54 m) at the 6MWT after PR, \**P*\<0.05 (Mann--Whitney *U*-test). The red line represents the ΔLzapp% cutoff value determined by the receiver operating characteristic (ROC) curve analysis showed in [Figure 4](#f4-copd-13-3131){ref-type="fig"}.\
**Abbreviations:** Lzapp, length of diaphragm zone of apposition; FRC, functional residual capacity; 6MWD, 6-minute walking distance; 6MWT, 6-minute walking test; PR, pulmonary rehabilitation.](copd-13-3131Fig2){#f2-copd-13-3131}

![Difference in ΔLzapp% between patients with a minimal clinically significant difference for CAT after PR.\
**Notes:** Box plots illustrating the change (%) of Lzapp at FRC between patients "slightly improved" (who achieved a \<2 points reduction of CAT score) or "markedly improved" (who achieved ≥2 points reduction in CAT score), \**P*\<0.05 (Mann--Whitney *U*-test). The red line represents the ΔLzapp% cutoff value determined by the receiver operating characteristic (ROC) curve analysis showed in [Figure 5](#f5-copd-13-3131){ref-type="fig"}.\
**Abbreviations:** Lzapp, length of diaphragm zone of apposition; FRC, functional residual capacity; CAT, COPD Assessment Test; PR, pulmonary rehabilitation.](copd-13-3131Fig3){#f3-copd-13-3131}

![Receiver operating characteristic (ROC) curve for ΔLzapp% in relation to 6MWD.\
**Note:** ROC curves estimate the ability of Lzapp change (as percentage of baseline) to predict a significant improvement in 6MWD after PR (AUC=0.83, cutoff ≥10%, sensitivity=83%, specificity=74%).\
**Abbreviations:** AUC, area under the curve; Lzapp, length of diaphragm zone of apposition; FRC, functional residual capacity; 6MWD, 6-minute walking distance; 6MWT, 6-minute walking test; PR, pulmonary rehabilitation.](copd-13-3131Fig4){#f4-copd-13-3131}

![Receiver operating characteristic (ROC) curve for ΔLzapp% in relation to CAT.\
**Note:** ROC curves estimate the ability of Lzapp change (as percentage of baseline) to predict a significant improvement in CAT after PR (AUC=0.76, cutoff \>9%, sensitivity=80%, specificity=62%).\
**Abbreviations:** AUC, area under the curve; Lzapp, length of diaphragm zone of apposition; FRC, functional residual capacity; CAT, COPD Assessment Test; PR, pulmonary rehabilitation.](copd-13-3131Fig5){#f5-copd-13-3131}

###### 

Baseline characteristics of the population

  Characteristics   N=25
  ----------------- ------------
                    
  Age (years)       70.6±6.5
  BMI (kg/m^2^)     25.04±4.88
  Gender n (%)      
   Female           2 (8.0%)
   Male             23 (92.0%)
  Smoking history   
   No smoker        1 (4%)
   Current smoker   7 (28%)
   Ex-smoker        17 (68%)
  GOLD stages       
   1                0 (0%)
   2                5 (20%)
   3                14 (56%)
   4                6 (24%)
  Charlson index    
   3                5 (20%)
   4                8 (32%)
   5                12 (48%)

**Note:** Data are presented as mean ± SD or n (%).

**Abbreviations:** BMI, body mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; Charlson index, Charlson comorbidity index.

###### 

Patients' characteristics before and after pulmonary rehabilitation

  N=25                 Pre-PR              Post-PR             *P*-value
  -------------------- ------------------- ------------------- -----------
                                                               
  Spirometry                                                   
   FVC%                83 (73--101)        89 (76--102)        0.020
   FEV~1~%             43 (34--50)         48 (39--55)         0.001
   PEF%                41 (40--50)         45 (40--51)         0.024
   FEV~1~/FVC%         41 (34--46)         53 (47--63)         \<0.001
   VR%                 132 (103--155)      129 (100--144)      0.002
   TLC%                105 (97--115)       102 (97--112)       0.040
   RV/TLC%             48 (38--52)         45 (36--50)         \<0.01
  Arterial blood gas                                           
   pH                  7.41 (7.40--7.42)   7.41 (7.40--7.42)   1
   SaO~2~%             94 (91--95)         93 (92--95)         0.008
   PaO~2~, mmHg        65 (59--70)         67 (60--71)         0.016
   PaCO~2~, mmHg       45 (41--49)         43 (40--45)         0.041
  6MWD (m)             250 (150--350)      300 (210--400)      \<0.001
  CAT                  26 (21--34)         24 (20--30)         \<0.001
  MRC                  4 (3--4)            3 (2--3)            \<0.001
  BODE                 6 (4--7)            4 (3--6)            0.001

**Note:** Data are presented as median (25th--75th percentiles).

**Abbreviations:** PFTs, pulmonary function tests; PR, pulmonary rehabilitation; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; PEF, peak forced expiratory flow; FEV~1~/FVC, Tiffeneau index; RV, residual volume; TLC, total lung capacity; RV/TLC, Motley index; ABG, arterial blood gas; 6MWD, 6-minute walking distance; CAT, COPD Assessment Test; MRC, Medical Research Council dyspnea score; BODE, BODE index (Body mass index, airflow Obstruction, Dyspnea, and Exercise).

###### 

Patients' ultrasonographic characteristics before and after pulmonary rehabilitation

  N=25                           Pre-PR        Post-PR       *P*-value
  ------------------------------ ------------- ------------- -----------
                                                             
  Diaphragm zapp (mm)                                        
   Lzapp TLC                     26 (18--31)   23 (19--26)   0.002
   Lzapp FRC                     38 (32--41)   41 (35--44)   \<0.001
   Szapp TLC                     5 (3--6)      4 (3--5)      0.001
   Szapp FRC                     4 (3--4)      3 (3--4)      0.027
  Diaphragmatic excursion (mm)                               
   Quiet breathing               23 (16--27)   27 (22--31)   \<0.001
   Deep breathing                36 (25--53)   50 (35--58)   \<0.001
  Rectus femoris area (m^2^)     4 (3--4)      4 (3--5)      \<0.001

**Note:** Data are presented as median (25th--75th percentiles).

**Abbreviations:** PR, pulmonary rehabilitation; zapp, diaphragm zone of apposition; Lzapp, length of diaphragm zone of apposition; Szapp, thickness of diaphragm zone of apposition; TLC, total lung capacity; FRC, functional residual capacity.

###### 

Patients' percentage of change of ultrasonographic measurements after pulmonary rehabilitation between "markedly improved" and "slightly improved" patients based on MCID at 6MWT

  Ultrasonographic measurements   6MWD \>54 m N=8    6MWD \<54 m N=17   *P*-value
  ------------------------------- ------------------ ------------------ -----------
                                                                        
  Diaphragm zapp                                                        
   ΔLzapp TLC%                    −15 (−26 to −12)   −18 (−23 to −9)    0.791
   ΔLzapp FRC%                    12 (10--15)        8 (3--11)          0.023
   ΔSzapp TLC%                    −5 (−8 to −2)      −5 (−10 to −3)     0.733
   ΔSzapp FRC%                    −6 (−9 to 0)       −7 (−11 to 0)      0.850
  Diaphragmatic excursion                                               
   ΔQuiet breathing, %            5 (2--10)          15 (3--44)         0.112
   ΔDeep breathing, %             6 (1--12)          17 (5--47)         0.132
  ΔRectus femoris area, %         10 (6--15)         8 (4--12)          0.850

**Note:** Data are presented as median (25th--75th percentiles).

**Abbreviations:** MCID, minimally clinical important difference; PR, pulmonary rehabilitation; zapp, diaphragm zone of apposition; Lzapp, length of diaphragm zone of apposition; Szapp, thickness of diaphragm zone of apposition; TLC, total lung capacity; FRC, functional residual capacity; 6MWD, 6-minute walking distance; 6MWT, 6-minute walking test.

###### 

Patients' percentage of change of ultrasonographic measurements after pulmonary rehabilitation between "markedly improved" and "slightly improved" patients based on MCID at CAT

  Ultrasonographic measurements   CAT ≥2 N=14        CAT \<2 N=11      *P*-value
  ------------------------------- ------------------ ----------------- -----------
                                                                       
  Diaphragm Zapp                                                       
   ΔLzapp TLC%                    −18 (−26 to −15)   −13 (−23 to −2)   0.197
   ΔLzapp FRC%                    11 (10--12)        4 (2--11)         0.043
   ΔSzapp TLC%                    −4 (−8 to −3)      −6 (−10 to −2)    0.863
   ΔSzapp FRC%                    −5 (−10 to 0)      −8 (−12 to 0)     0.756
  Diaphragmatic excursion                                              
   ΔQuiet breathing, %            10 (1--15)         38 (3--60)        0.180
   ΔDeep breathing, %             14 (6--31)         17 (3--47)        0.913
  ΔRectus femoris area, %         8 (3--17)          8 (4--12)         1

**Note:** Data are presented as median (25th--75th percentiles).

**Abbreviations:** MCID, minimally clinical important difference; PR, pulmonary rehabilitation; Zapp, diaphragm zone of apposition; Lzapp, length of diaphragm zone of apposition; Szapp, thickness of diaphragm zone of apposition; TLC, total lung capacity; FRC, functional residual capacity; CAT, COPD Assessment Test.
